Novosanis and nRichDX Urine Collection and Extraction Solutions

First-void urine as a non-invasive proxy for plasma in prostate cancer-related liquid biopsy applications.

Organizations: Novosanis and nRichDX

Venue: American Association for Cancer Research 2024 Annual Meeting

Date: April 2024

This poster, jointly presented with Novosanis, describes a comparison of first-void urine samples with plasma samples. Further investigations are needed to evaluate clinical samples and biomarkers to establish a robust

correlation between cfDNA levels and cancer types and stages. This study highlights the potential of first-void urine samples as a reliable proxy for blood-based liquid biopsy applications.

Enhanced Extraction and Preservation of Circulating Cell-Free RNA from 50 mL Cell-Free Urine

Organizations: nRichDX and Agilent

Venue: Association for Molecular Pathology (AMP) 30th Annual Meeting and Expo

Date: November 2024

This poster describes the extraction of 12, 50 mL urine samples spiked with free RNA extracted from LnCAP cells containing the PTEN mutation. Parallel extractions were performed using the Revolution cfTNA Max 50 Kit and the Zymo ZR Urine RNA Isolation Kit and the Norgen Urine Cell-free Circulating and Viral Nucleic Acid Purification Maxi Kit for purposes of comparison.

Integrated Liquid Biopsy for Prostate Cancer: Capturing Circulating Tumor Cells and Urinary Cell-Free Total Nucleic Acid

Organizations: Anchor Molecular and nRichDX

Venue: Cancer Genomics Consortium (CGC) 2024 15th Annual Meeting

Date: August 2024

This poster describes the extraction of LNCaP prostate cancer cells from whole blood and the TMPRSS2-ERG prostate cancer RNA fusion as circulating cell-free nucleic acid from urine using nRichDX's Revolution CTC Enrichment (Epithelial) Kit and the Revolution cfTNA Max 20 Kit.

Enhancing urine-based cfDNA detection for prostate cancer diagnosis through increased input volume

Organizations: Agilent and nRichDX

Venue: American Association for Cancer Research 2024 Annual Meeting

Date: April 2024

This poster, jointly presented with Agilent, describes sensitive cfDNA detection using the enhanced nRicher Cartridge input urine volume in a single extraction. TapeStation tracings demonstrated proportionally increasing cfDNA yield with increasing sample volume when using the nRichDX Revolution system. qPCR confirmed the detection of the PIK3CA prostate cancer mutation in all cfDNA eluates extracted using the nRichDX Revolution system. The mutation was not detected in any eluates extracted with the MagMax cfDNA Isolation kit.

Amit Arora, PhD, Sr. Scientist at DNA Genotek - Colli-Pee™ for urine collection and UAS™ for preservation (10 min.) View the segment.

Nafiseh Jafari, PhD, Director of R&D at nRichDX - cfDNA and ctDNA extraction from urine using the Revolution Sample Prep System (10 min.) View the segment.

KEYNOTE: Simpa Salami, PhD, MPH, Assistant Professor of Urology at the University of Michigan and Co-Director, Liquid Biopsy Core, Rogel Cancer Center - "Molecular Profiling of Urine for Prostate Cancer Diagnosis: Opportunities and Challenges" (20 min.) View the segment.

Novosanis, a subsidiary of OraSure Technologies, Inc., is an innovator of first-void urine (FVU) urine sample collection with the Colli-Pee™ sample collection device family to improve the quality of diagnostic tests for infectious diseases and oncology. The Colli-Pee UAS™ devices provide non-invasive, self-collected, and volumetric sampling to standardize FVU collection, with a unique design to enable the immediate mixing of urine and preservative for FVU sample stability. Offering various sizes to capture a range of urine volumes for different application purposes, Novosanis is pioneering FVU sample collection as an alternative to invasive sampling -demonstrated by strong clinical research outcomes, patient preference and affordability.

The Colli-Pee™is RUO-labeled in the U.S.

For Research Use Only. Not for use in diagnostic procedures.

https://novosanis.com/

nRichDX® is an emerging leader in liquid biopsy sample prep solutions that enable customers to extract much more analysis-ready cfDNA, cfRNA, and CTCs from blood and urine as compared to existing methods. The company’s patented Revolution Sample Prep System™ is the first and only high-yield, high-recovery, IVD-labeled liquid biopsy sample prep platform that can process a wide range of total volumes from 1 mL - 50 mL or more in a single semi-automated extraction, without using schemes like pooling, bead recycling, and transfer steps that other systems require. nRichDX solves one of precision medicine’s greatest problems – inaccurate or failed liquid biopsies due to a lack of sufficient analytes. The Revolution System greatly enhances assay sensitivity and by delivering more analytes enables earlier detection, monitoring, timely treatment, and optimal patient outcomes.